Influenza Infection Triggers Disease in a Genetic Model of Experimental
Influenza infection triggers disease in a genetic model PNAS PLUS of experimental autoimmune encephalomyelitis Stephen Blackmorea, Jessica Hernandeza, Michal Judaa, Emily Ryderb, Gregory G. Freunda,c, Rodney W. Johnsona,b,d, and Andrew J. Steelmana,b,d,1 aDepartment of Animal Sciences, University of Illinois Urbana–Champaign, Urbana, IL 61801; bNeuroscience Program, University of Illinois Urbana–Champaign, Urbana, IL 61801; cDepartment of Pathology, University of Illinois Urbana–Champaign, Urbana, IL 61801; and dDivision of Nutritional Sciences, University of Illinois Urbana–Champaign, Urbana, IL 61801 Edited by Lawrence Steinman, Stanford University School of Medicine, Stanford, CA, and approved June 13, 2017 (received for review December 13, 2016) Multiple sclerosis (MS) is an autoimmune disease of the central affect the progression of many neurological diseases including nervous system. Most MS patients experience periods of symptom Alzheimer’s disease (10, 11), Parkinson’s disease (12), and exacerbation (relapses) followed by periods of partial recovery multiple sclerosis (13–17). (remission). Interestingly, upper-respiratory viral infections increase We are interested in determining how upper-respiratory in- the risk for relapse. Here, we used an autoimmune-prone T-cell fection contributes to the progression of neurological dis- receptor transgenic mouse (2D2) and a mouse-adapted human eases including multiple sclerosis (MS), the most prominent influenza virus to test the hypothesis that upper-respiratory viral autoimmune-mediated demyelinating and neurodegenerating infection can cause glial activation, promote immune cell trafficking disease of the CNS. The majority of MS patients exhibit an os- to the CNS, and trigger disease. Specifically, we inoculated 2D2 mice cillating disease course that is characterized by relatively short with influenza A virus (Puerto Rico/8/34; PR8) and then monitored periods of neurological dysfunction followed by periods of re- them for symptoms of inflammatory demyelination.
[Show full text]